一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括silevertinib (BDTX-1535) monotherapy，当前状态为研究进行中，已停止招募。登记地点显示中国Birmingham、Gilbert、Huntington Beach、Irvine等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
silevertinib (BDTX-1535) monotherapy · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of Alabama · Birmingham
- Banner MD Anderson Cancer Center · Gilbert
- City of Hope Huntington Beach · Huntington Beach
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine
- Cedars Sinai Medical Center · Los Angeles
- Sibley Memorial Hospital Johns Hopkins Medicine · Washington D.C.
- Mayo Clinic- Jacksonville · Jacksonville
- Miami Cancer Institute - Baptist Health South Florida · Miami
- UHP- University of Hawaii Cancer Center · Honolulu
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University · Chicago
- University of Kansas Cancer Center · Fairway
- Johns Hopkins Bayview Medical Center · Baltimore
- Dana-Farber Cancer Institute · Boston
- Mayo Clinic- Rochester · Rochester
- Siteman Cancer Center · St Louis
- Memorial Sloan Kettering Cancer Center · New York
- Columbia University Irving Medical Center · New York
- Montefiore Medical Center · The Bronx
- UNC Hospitals - Lineberger Comprehensive Cancer Center · Chapel Hill
- University of Pittsburgh Medical Center - Hillman Cancer Center · Pittsburgh
- Tennessee Oncology · Nashville
- The University of Texas MD Anderson Cancer Center · Houston
- Inova Schar Cancer Institute · Fairfax
- Next Ocology · Fairfax
- Fred Hutchinson Cancer Center/University of Washington · Seattle
公开的入选条件
- Required for locally advanced or metastatic NSCLC:
- * Measurable disease by RECIST 1.1 criteria.
- * Adequate bone marrow or organ function.
- * Life expectancy of ≥ 3 months.
- * Sufficient performance status.
- * Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
- * Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):
- Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05256290；登记信息更新于 2026-07-22。